Skip to main content

CSP-2503









CSP-2503


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search










































CSP-2503
CSP-2503-structure.png
Clinical data
ATC code
  • none
Identifiers

PubChem CID
  • 10317515
ChemSpider

  • 8492979 ☑Y
ChEMBL

  • ChEMBL285066 ☑Y
Chemical and physical data
Formula
C22H26N4O2
Molar mass 378.47 g/mol
3D model (JSmol)
  • Interactive image

.mw-parser-output .nobold{font-weight:normal}
  (verify)

CSP-2503 is a potent and selective 5-HT1A receptor agonist, 5-HT2A receptor antagonist, and 5-HT3 receptor antagonist of the phenylpiperazine class.[1] First synthesized in 2003, it was designed based on computational models and QSAR studies.[2][3] In rat studies, CSP-2503 has demonstrated anxiolytic effects, and thus has been suggested as a treatment for anxiety in humans with a multimodal mechanism of action.[1]



See also[edit]



  • Naphthylpiperazine

  • S-14,671



References[edit]





  1. ^ ab Delgado M, Caicoya AG, Greciano V, et al. (March 2005). "Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors". European Journal of Pharmacology. 511 (1): 9–19. doi:10.1016/j.ejphar.2005.01.032. PMID 15777774..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ López-Rodríguez ML, Morcillo MJ, Fernández E, et al. (April 2003). "Design and synthesis of S-(−)-2-[[4-(napht-1-yl)piperazin-1-yl]methyl]-1,4-dioxoperhydropyrrolo[1,2-a]pyrazine (CSP-2503) using computational simulation. A 5-HT1A receptor agonist". Bioorganic & Medicinal Chemistry Letters. 13 (8): 1429–32. doi:10.1016/S0960-894X(03)00160-4. PMID 12668005.


  3. ^ López-Rodríguez ML, Morcillo MJ, Fernández E, et al. (April 2005). "Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT(1A)R agonists with selectivity over alpha1-adrenoceptors". Journal of Medicinal Chemistry. 48 (7): 2548–58. doi:10.1021/jm048999e. PMID 15801844.














Retrieved from "https://en.wikipedia.org/w/index.php?title=CSP-2503&oldid=753700252"





Navigation menu

























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.688","walltime":"0.863","ppvisitednodes":{"value":4798,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":318731,"limit":2097152},"templateargumentsize":{"value":4743,"limit":2097152},"expansiondepth":{"value":14,"limit":40},"expensivefunctioncount":{"value":2,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":10703,"limit":5000000},"entityaccesscount":{"value":2,"limit":400},"timingprofile":["100.00% 593.011 1 -total"," 66.48% 394.207 1 Template:Drugbox"," 48.10% 285.249 1 Template:Infobox"," 21.52% 127.623 19 Template:Navbox"," 18.25% 108.203 1 Template:Reflist"," 15.86% 94.031 3 Template:Cite_journal"," 15.06% 89.323 16 Template:Unbulleted_list"," 7.83% 46.404 1 Template:Serotonergics"," 7.09% 42.049 1 Template:Infobox_drug/chemical_formula"," 5.68% 33.704 1 Template:Anxiolytics"]},"scribunto":{"limitreport-timeusage":{"value":"0.209","limit":"10.000"},"limitreport-memusage":{"value":4281900,"limit":52428800}},"cachereport":{"origin":"mw1331","timestamp":"20181216015716","ttl":1900800,"transientcontent":false}}});});{"@context":"https://schema.org","@type":"Article","name":"CSP-2503","url":"https://en.wikipedia.org/wiki/CSP-2503","sameAs":"http://www.wikidata.org/entity/Q12744889","mainEntity":"http://www.wikidata.org/entity/Q12744889","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https://www.wikimedia.org/static/images/wmf-hor-googpub.png"}},"datePublished":"2010-08-22T17:03:09Z","dateModified":"2016-12-08T18:27:47Z","image":"https://upload.wikimedia.org/wikipedia/commons/a/a3/CSP-2503-structure.png","headline":"chemical compound"}(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgBackendResponseTime":165,"wgHostname":"mw1268"});});

Popular posts from this blog

Full-time equivalent

Bicuculline

さくらももこ